Arterial hypertension was the “school” of the methodology of clinical trials. All readers who started to work in Pharmaceutical Medicine/Medicines Development in the 70s and 80s will certainly remember the great enthusiasm caused by the discovery of the new classes of anti-hypertensive agents (beta-blockers, calcium antagonists, ACE-inhibitors and finally sartans), and the rigid methodology which was applied, for the first time, for their clinical development. These significant achievements contributed to a good control of arterial hypertension, saving millions of lives from cardiovascular events.
Today arterial hypertension is very easily managed by all the drugs available, very effective and well tolerated: however we still have a minority of patients who are refractory to the available therapies. It is therefore with special interest to read the full paper of a Phase II trial of a new antihypertensive agent, specifically addressed to this niche population of patients.1
Keep reading here
References
- Freeman, M. W., Halvorsen, Y., Marshall, W., Pater, M., Isaacsohn, J., Pearce, C., Murphy, B., Alp, N., Srivastava, A., Bhatt, D. L., & Brown, M. J. (2022). Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. The New England Journal of Medicine, 388(5), 395–405. https://doi.org/10.1056/nejmoa2213169
Disclaimers
- The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
- Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
- No official support by any organization(s) has been provided or should be inferred
